News

Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma (bone marrow cancer) patients Rotterdam, the Netherlands, 8 September 2015 – Researchers at the...

Key additions to the management team as SkylineDx accelerates its development of gene signature-based diagnostics and prepares for the launch of its first product Rotterdam, The Netherlands, 19 August 2015 – SkylineDx, a...

Test of Dutch-based SkylineDx gives patients better insight in their chances and enables clinicians to adjust their treatment Rotterdam, 2 July 2015 – SkylineDx, an innovative biotechnology company specialising in the development and...

Boston (U.S.) – Rotterdam (NL), June 8, 2015. On the 13th of June SkylineDx will present an abstract detailing the comparison of SKY92 GEP, IFISH AND ISS for risk identification in Multiple...